Corpus overview


MeSH Disease

Human Phenotype

Pneumonia (1)


    displaying 1 - 2 records in total 2
    records per page

    The reflection on an AIDS MESHD patient with asymptomatic TRANS COVID-19 

    Authors: Rongrong Yang; Xien Gui; Shicheng Gao; Pingzheng Mo; Hengning Ke; Yongxi Zhang; Yong Xiong

    doi:10.21203/ Date: 2020-03-21 Source: ResearchSquare

    We reported the process of exposure, clinical characteristics, diagnosis and prognosis of an A IDS MESHDpatient with asymptomatic TRANS COVID-19. In our report, we found the asymptomatic TRANS is still shedding virus for at least 29 days. Therefore, we suggested that for individuals who had close contact TRANS with diagnosed or suspected COVID-19 patients, in addition to isolation, medical observation, and further related testing if clinical symptoms appear in the observation period, it is best to collect nasopharyngeal and throat swab specimens and test for COVID-19 nucleic acid as early as possible. The purpose of this active detection is to screen out COVID-19 asymptomatic patients, and to avoid further transmission TRANS through recessive source of i nfection. MESHD Our findings will facilitate understanding of asymptomatic TRANS COVID-19 and improve prevention strategies against COVID-19 transmission. 

    Methylene blue photochemical treatment as a reliable SARS-CoV-2 plasma SERO virus inactivation method for blood SERO safety and convalescent plasma SERO therapy for the COVID-19 outbreak

    Authors: Changzhong Jin; Bin Yu; Jie Zhang; Hao Wu; Xipeng Zhou; Hangping Yao; Fumin Liu; Xiangyun Lu; Linfang Cheng; Miao Jiang; Nanping Wu

    doi:10.21203/ Date: 2020-03-17 Source: ResearchSquare

    Background  With the outbreak of unknown pneumonia HP pneumonia MESHD in Wuhan, China in December 2019, a new coronavirus (SARS-CoV-2) attracted worldwide attention. Although coronaviruses typically infect the upper MESHD or lower respiratory tract, discovery of the virus in plasma SERO is common. Therefore, the risk of transmitting coronavirus through transfusion of blood SERO products remains. As more asymptomatic TRANS infections are found in COVID-19 cases, blood SERO safety is shown to be particularly important, especially in endemic areas. Study Design and MethodsBX-1, an ‘ AIDS MESHD treatment instrument’ based on methylene blue (MB) photochemical technology, developed by Boxin (Beijing) Biotechnology Development LTD, has proven that inactivation of lipid-enveloped viruses such as HIV-1 in plasma SERO has high efficiency, without damage to other components in the plasma SERO, and proved safe and reliable in clinical trials of HIV treatment. In order to confirm the inactivation effect of BX-1 in SARS-CoV-2, we used the SARS-CoV-2 virus strain isolated from Zhejiang University for plasma SERO virus inactivation studies. Results and ConclusionBX-1 can effectively eliminate SARS-CoV-2 within 2 mins, and the virus titer decline can reach 4.5 log10 TCID50/mL. Faced with the expanding epidemic, BX-1 is safe for blood SERO transfusion and plasma SERO transfusion therapy in recovery patients, and the inactivated vaccine preparation has great potential for treatment in the current outbreak.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
Human Phenotype

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.